NVIDIA Locks In Dual Pharma Deals With Eli Lilly and Thermo Fisher, Making BioNeMo Drug Discovery's Core AI Layer
NVIDIA secured simultaneous partnerships with Eli Lilly and Thermo Fisher in January 2026, anchoring BioNeMo as the foundational AI infrastructure for pharmaceutical research. The deals triggered a wave of AI foundation model launches from specialized biotech firms including Basecamp Research, Boltz, Owkin, Edison Scientific, and Natera. The dynamic mirrors cloud infrastructure consolidation — one dominant platform enabling a specialized application ecosystem above it.
Salvado•